|
US20030206887A1
(en)
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
|
DK1129064T3
(da)
|
1998-11-12 |
2008-04-28 |
Invitrogen Corp |
Transfektionsreagenser
|
|
US20050020525A1
(en)
*
|
2002-02-20 |
2005-01-27 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
|
WO2006006948A2
(en)
|
2002-11-14 |
2006-01-19 |
Dharmacon, Inc. |
METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
|
|
EP2305812A3
(en)
|
2002-11-14 |
2012-06-06 |
Dharmacon, Inc. |
Fuctional and hyperfunctional sirna
|
|
CN1257284C
(zh)
|
2003-03-05 |
2006-05-24 |
北京博奥生物芯片有限责任公司 |
一种体外阻断乙肝病毒表达的方法
|
|
DK1620544T3
(en)
|
2003-04-17 |
2019-01-14 |
Alnylam Pharmaceuticals Inc |
MODIFIED iRNA AGENTS
|
|
EP1752536A4
(en)
|
2004-05-11 |
2008-04-16 |
Alphagen Co Ltd |
POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
|
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
|
EP1791567B1
(en)
|
2004-08-10 |
2015-07-29 |
Alnylam Pharmaceuticals Inc. |
Chemically modified oligonucleotides
|
|
KR20100060018A
(ko)
|
2005-03-09 |
2010-06-04 |
재단법인 목암생명공학연구소 |
작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물
|
|
ES2874149T3
(es)
|
2006-05-11 |
2021-11-04 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para inhibir la expresión del gen PCSK9
|
|
AU2007275365A1
(en)
|
2006-07-17 |
2008-01-24 |
Sirna Therapeutics Inc. |
RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
|
|
WO2008109369A2
(en)
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
|
|
WO2009082607A2
(en)
|
2007-12-04 |
2009-07-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
|
AU2014208251B2
(en)
|
2007-12-04 |
2016-07-14 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
|
MX2010008394A
(es)
|
2008-01-31 |
2010-11-12 |
Alnylam Pharmaceuticals Inc |
Metodos optimizados para administracion de arndc focalizando el gen pcsk9.
|
|
US10131904B2
(en)
|
2008-02-11 |
2018-11-20 |
Rxi Pharmaceuticals Corporation |
Modified RNAi polynucleotides and uses thereof
|
|
CN101603042B
(zh)
|
2008-06-13 |
2013-05-01 |
厦门大学 |
可用于乙型肝炎病毒感染治疗的rna干扰靶点
|
|
WO2010012244A1
(zh)
|
2008-08-01 |
2010-02-04 |
苏州瑞博生物技术有限公司 |
乙型肝炎病毒基因的小核酸干扰靶位点序列和小干扰核酸及组合物和应用
|
|
MX2011004097A
(es)
|
2008-10-15 |
2011-07-28 |
Isis Pharmaceuticals Inc |
Modulacion de la expresion del factor 11.
|
|
US20120227119A1
(en)
|
2008-12-17 |
2012-09-06 |
Australian Poultry Crc Pty Ltd |
Methods of Modulating the Sex of Avians
|
|
CA2750561C
(en)
|
2009-01-26 |
2017-10-10 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for silencing apolipoprotein c-iii expression
|
|
EP2669290A1
(en)
|
2009-03-02 |
2013-12-04 |
Alnylam Pharmaceuticals Inc. |
Nucleic Acid Chemical Modifications
|
|
NZ595891A
(en)
|
2009-04-15 |
2013-06-28 |
Isis Pharmaceuticals Inc |
Modulation of inflammatory responses by factor xi
|
|
KR101224828B1
(ko)
|
2009-05-14 |
2013-01-22 |
(주)바이오니아 |
ｓｉＲＮＡ 접합체 및 그 제조방법
|
|
WO2010147992A1
(en)
|
2009-06-15 |
2010-12-23 |
Alnylam Pharmaceuticals, Inc. |
Methods for increasing efficacy of lipid formulated sirna
|
|
NZ597504A
(en)
|
2009-06-15 |
2013-10-25 |
Alnylam Pharmaceuticals Inc |
Lipid formulated dsrna targeting the pcsk9 gene
|
|
JP2014501097A
(ja)
|
2009-07-06 |
2014-01-20 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
生物由来物質の産生を高めるための組成物及び方法
|
|
CA2677068A1
(en)
|
2009-09-01 |
2011-03-01 |
Mdrna, Inc. |
Nucleic acid compounds for inhibiting gene expression and uses thereof
|
|
WO2011028938A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
|
US9187746B2
(en)
|
2009-09-22 |
2015-11-17 |
Alnylam Pharmaceuticals, Inc. |
Dual targeting siRNA agents
|
|
US8653047B2
(en)
|
2010-01-08 |
2014-02-18 |
Isis Pharmaceuticals, Inc. |
Modulation of angiopoietin-like 3 expression
|
|
CN102140460B
(zh)
|
2010-01-29 |
2012-12-12 |
苏州瑞博生物技术有限公司 |
小干扰核酸和药物组合物及其制药应用
|
|
CN102140458B
(zh)
*
|
2010-01-29 |
2013-05-22 |
苏州瑞博生物技术有限公司 |
小干扰核酸和药物组合物及其制药应用
|
|
CN102140459B
(zh)
|
2010-01-29 |
2013-04-03 |
苏州瑞博生物技术有限公司 |
一种小干扰核酸和药物组合物及其制药应用
|
|
CN102140461B
(zh)
|
2010-01-29 |
2012-12-05 |
苏州瑞博生物技术有限公司 |
小干扰核酸和药物组合物及其制药应用
|
|
DK2539451T3
(da)
|
2010-02-24 |
2016-04-04 |
Arrowhead Res Corp |
Sammensætninger til målrettet tilførsel af siRNA
|
|
US8691580B2
(en)
*
|
2010-04-09 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Single chemical entities and methods for delivery of oligonucleotides
|
|
KR101869570B1
(ko)
|
2010-04-28 |
2018-06-20 |
아이오니스 파마수티컬즈, 인코포레이티드 |
변형된 뉴클레오사이드 및 그로부터 제조된 올리고머 화합물
|
|
WO2011154331A1
(en)
|
2010-06-10 |
2011-12-15 |
F. Hoffmann-La Roche Ag |
Polymers for delivery of nucleic acids
|
|
CN102344477B
(zh)
*
|
2010-07-27 |
2015-04-08 |
苏州瑞博生物技术有限公司 |
一种核苷酸和/或寡核苷酸及其制备方法
|
|
WO2012024170A2
(en)
|
2010-08-17 |
2012-02-23 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
WO2012058693A2
(en)
|
2010-10-29 |
2012-05-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibition of pcsk9 genes
|
|
US20120136073A1
(en)
|
2010-11-15 |
2012-05-31 |
Life Technologies Corporation |
Amine-Containing Transfection Reagents and methods for making and using same
|
|
US8501930B2
(en)
|
2010-12-17 |
2013-08-06 |
Arrowhead Madison Inc. |
Peptide-based in vivo siRNA delivery system
|
|
ES2605990T3
(es)
|
2010-12-29 |
2017-03-17 |
F. Hoffmann-La Roche Ag |
Conjugados de molécula pequeña para la administración intracelular de ácidos nucleicos
|
|
CA2823776A1
(en)
|
2011-01-06 |
2012-07-12 |
Dyax Corp. |
Plasma kallikrein binding proteins
|
|
KR102365961B1
(ko)
|
2011-03-29 |
2022-02-23 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
|
CN102719434A
(zh)
|
2011-03-31 |
2012-10-10 |
百奥迈科生物技术有限公司 |
抑制rna干扰脱靶效应的特异性修饰
|
|
KR101870915B1
(ko)
|
2011-04-08 |
2018-06-25 |
유니버시티 오브 레스터 |
Ｍａｓｐ-2 의존적 보체 활성화와 관련된 질병을 치료하는 방법
|
|
CN102727907B
(zh)
|
2011-04-13 |
2015-03-11 |
苏州瑞博生物技术有限公司 |
一种小干扰rna药物的给药系统和制剂
|
|
CN107854478A
(zh)
|
2011-04-27 |
2018-03-30 |
Ionis制药公司 |
载脂蛋白ciii（apociii）表达的调节
|
|
ES2923573T3
(es)
|
2011-06-21 |
2022-09-28 |
Alnylam Pharmaceuticals Inc |
Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas
|
|
HRP20181564T1
(hr)
|
2011-06-30 |
2018-11-30 |
Arrowhead Pharmaceuticals, Inc. |
Pripravci i postupci za inhibiciju ekspresije gena virusa hepatitisa b
|
|
CN103073726B
(zh)
|
2011-10-26 |
2015-09-23 |
苏州瑞博生物技术有限公司 |
嵌段共聚物与液体组合物和核酸制剂及其制备方法和应用
|
|
KR102451116B1
(ko)
|
2011-10-27 |
2022-10-06 |
메사추세츠 인스티튜트 오브 테크놀로지 |
약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
|
|
WO2013070771A1
(en)
|
2011-11-07 |
2013-05-16 |
Isis Pharmaceuticals, Inc. |
Administration of factor xi antisense oligonucleotides
|
|
AR090905A1
(es)
|
2012-05-02 |
2014-12-17 |
Merck Sharp & Dohme |
Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
|
|
AU2013299717B2
(en)
|
2012-08-06 |
2018-06-28 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugated RNA agents and process for their preparation
|
|
US10077443B2
(en)
|
2012-11-15 |
2018-09-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
|
FR2998748B1
(fr)
|
2012-11-23 |
2015-04-10 |
Commissariat Energie Atomique |
Dispositif et procede de retransmission de donnees dans un commutateur reseau
|
|
US10125369B2
(en)
|
2012-12-05 |
2018-11-13 |
Alnylam Pharmaceuticals, Inc. |
PCSK9 iRNA compositions and methods of use thereof
|
|
CN104955952A
(zh)
|
2013-01-30 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
Lna寡核苷酸碳水化合物缀合物
|
|
CA3216595A1
(en)
|
2013-03-14 |
2014-10-02 |
Kevin Fitzgerald |
Complement component c5 irna compositions and methods of use thereof
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
WO2014182661A2
(en)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
|
CN104107437B
(zh)
|
2013-06-09 |
2015-08-26 |
厦门成坤生物技术有限公司 |
一种用于治疗乙型病毒性肝炎的rna干扰组合物及其制备方法
|
|
EP3564374A1
(en)
|
2013-06-21 |
2019-11-06 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulation of target nucleic acids
|
|
JP2016528890A
(ja)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
|
|
JP6702862B2
(ja)
*
|
2013-07-11 |
2020-06-03 |
アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法
|
|
US9889200B2
(en)
|
2013-07-31 |
2018-02-13 |
Qbi Enterprises Ltd. |
Sphingolipid-polyalkylamine-oligonucleotide compounds
|
|
KR102365486B1
(ko)
|
2013-08-28 |
2022-02-18 |
아이오니스 파마수티컬즈, 인코포레이티드 |
프리칼리크레인 (pkk) 발현의 조절
|
|
EP3052627B1
(en)
|
2013-10-04 |
2018-08-22 |
Novartis AG |
Novel formats for organic compounds for use in rna interference
|
|
US10607717B2
(en)
|
2013-11-06 |
2020-03-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method for subtyping lymphoma types by means of expression profiling
|
|
CN111394355A
(zh)
|
2013-12-24 |
2020-07-10 |
Ionis制药公司 |
促血管生成素样3表达的调节
|
|
AU2015209481C1
(en)
|
2014-01-21 |
2020-10-29 |
Takeda Pharmaceutical Company Limited |
Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
|
|
WO2015113922A1
(en)
|
2014-01-30 |
2015-08-06 |
Roche Innovation Center Copenhagen A/S |
Poly oligomer compound with biocleavable conjugates
|
|
WO2015148580A2
(en)
|
2014-03-25 |
2015-10-01 |
Arcturus Therapeutics, Inc. |
Una oligomers having reduced off-target effects in gene silencing
|
|
PT3137605T
(pt)
|
2014-05-01 |
2020-12-18 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão de angiopoietina de tipo 3
|
|
EP3862362A3
(en)
|
2014-05-01 |
2021-10-27 |
Ionis Pharmaceuticals, Inc. |
Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
|
|
JP2017522046A
(ja)
|
2014-06-06 |
2017-08-10 |
ソルスティス バイオロジクス，リミティッド |
生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物
|
|
EP3736334A1
(en)
|
2014-07-16 |
2020-11-11 |
Arrowhead Pharmaceuticals, Inc. |
Rnai compositions to treat apoc3-related diseases
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
CN104232644B
(zh)
|
2014-09-03 |
2016-10-12 |
浙江大学 |
一种特异抑制XOR基因表达的siRNA及其应用
|
|
TWI710633B
(zh)
*
|
2014-11-10 |
2020-11-21 |
美商阿尼拉製藥公司 |
Ｂ型肝炎病毒（ＨＢＶ）ｉＲＮＡ組成物及其用途方法
|
|
HK1244843A1
(zh)
*
|
2014-11-17 |
2018-08-17 |
Alnylam Pharmaceuticals, Inc. |
载脂蛋白c3(apoc3)irna组合物及其使用方法
|
|
SG10202013032YA
(en)
|
2014-12-15 |
2021-02-25 |
Univ Emory |
Phosphoramidates for the treatment of hepatitis b virus
|
|
US10036017B2
(en)
|
2015-02-17 |
2018-07-31 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of complement component 5(C5) by double-stranded RNA
|
|
JP2018509913A
(ja)
|
2015-03-17 |
2018-04-12 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
第ｘｉｉ因子の遺伝子発現を阻害するための組成物と方法
|
|
CA2979998A1
(en)
|
2015-03-20 |
2016-09-29 |
Protiva Biotherapeutics, Inc. |
Compositions and methods for treating hypertriglyceridemia
|
|
EA201792263A1
(ru)
|
2015-04-13 |
2018-08-31 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA ПРОТИВ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
KR102827366B1
(ko)
|
2015-05-06 |
2025-07-03 |
알닐람 파마슈티칼스 인코포레이티드 |
인자 ＸＩＩ(하게만 인자)(Ｆ12), 칼리크레인 Ｂ, 혈장(플레처 인자) 1(ＫＬＫＢ1) 및 키니노겐 1(ＫＮＧ1) ｉＲＮＡ 조성물 및 그의 이용 방법
|
|
CN104922141B
(zh)
|
2015-05-28 |
2016-05-25 |
厦门成坤生物技术有限公司 |
一种用于治疗乙型病毒性肝炎的siRNA组合物
|
|
EP4365291A3
(en)
|
2015-06-12 |
2024-08-14 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
CN107849567B
(zh)
|
2015-06-26 |
2024-07-23 |
苏州瑞博生物技术股份有限公司 |
一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用
|
|
JP6924744B2
(ja)
*
|
2015-07-17 |
2021-08-25 |
アークトゥラス・セラピューティクス・インコーポレイテッドＡｒｃｔｕｒｕｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． |
Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用
|
|
TW201718620A
(zh)
|
2015-07-27 |
2017-06-01 |
阿尼拉製藥公司 |
黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用方法
|
|
CN108350455A
(zh)
*
|
2015-07-29 |
2018-07-31 |
阿布特斯生物制药公司 |
用于使b型肝炎病毒基因表达沉默的组合物和方法
|
|
KR20180038465A
(ko)
|
2015-08-07 |
2018-04-16 |
애로우헤드 파마슈티컬스 인코포레이티드 |
Ｂ형 간염 바이러스 감염에 대한 ｒｎａｉ 치료법
|
|
CN118697894A
(zh)
|
2015-08-25 |
2024-09-27 |
阿尔尼拉姆医药品有限公司 |
用于治疗前蛋白转化酶枯草杆菌蛋白酶kexin(pcsk9)基因相关障碍的方法和组合物
|
|
WO2017055627A1
(en)
|
2015-10-02 |
2017-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Apoc3 mutations for the diagnosis and therapy of hereditary renal amyloidosis disease
|
|
WO2017100542A1
(en)
|
2015-12-10 |
2017-06-15 |
Alnylam Pharmaceuticals, Inc. |
Sterol regulatory element binding protein (srebp) chaperone (scap) irna compositions and methods of use thereof
|
|
EP3400301A4
(en)
|
2016-01-08 |
2019-11-27 |
Alnylam Pharmaceuticals, Inc. |
AGAINST FACTOR XII (HAGEMAN FACTOR) (F12) POLYNUCLEOTIDE AGENTS AND METHOD OF USE THEREOF
|
|
AU2017213404A1
(en)
|
2016-01-29 |
2018-09-20 |
Kyowa Kirin Co., Ltd. |
Nucleic acid conjugate
|
|
MA45295A
(fr)
|
2016-04-19 |
2019-02-27 |
Alnylam Pharmaceuticals Inc |
Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
|
|
IL293308B2
(en)
|
2016-04-28 |
2024-12-01 |
Regeneron Pharma |
Methods for treating patients with familial hypercholesterolemia
|
|
JOP20190015A1
(ar)
|
2016-08-04 |
2019-02-04 |
Arrowhead Pharmaceuticals Inc |
عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
|
|
JP2019532027A
(ja)
|
2016-08-17 |
2019-11-07 |
ソルスティス バイオロジクス，リミティッド |
ポリヌクレオチド構築物
|
|
MX2018009853A
(es)
|
2016-09-02 |
2018-11-09 |
Arrowhead Pharmaceuticals Inc |
Ligandos de direccion.
|
|
LT3529360T
(lt)
|
2016-10-18 |
2024-07-25 |
Novartis Ag |
Metodai, skirti širdies ir kraujagyslių ligų prevencijai mažinant proproteinų konvertazės subtilizino keksino 9 (pcsk9) baltymo kiekį
|
|
CN113652431A
(zh)
|
2016-12-21 |
2021-11-16 |
苏州瑞博生物技术股份有限公司 |
一种小干扰核酸和药物组合物及其用途
|
|
CN108239644B
(zh)
|
2016-12-23 |
2021-05-28 |
苏州瑞博生物技术股份有限公司 |
一种小干扰核酸和药物组合物及其用途
|
|
CN108265052B
(zh)
|
2016-12-30 |
2021-05-28 |
苏州瑞博生物技术股份有限公司 |
一种小干扰核酸和药物组合物及其用途
|
|
AU2018213379A1
(en)
|
2017-01-30 |
2019-07-18 |
Arrowhead Pharmaceuticals Inc. |
Compositions and methods for inhibition of factor XII gene expression
|
|
WO2018191278A2
(en)
|
2017-04-11 |
2018-10-18 |
Arbutus Biopharma Corporation |
Targeted compositions
|
|
CN108929870B
(zh)
|
2017-05-19 |
2020-01-24 |
百奥迈科生物技术有限公司 |
抑制HBV的siRNA分子及其应用
|
|
JP2020522265A
(ja)
|
2017-06-02 |
2020-07-30 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物及びその使用方法
|
|
WO2019105403A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CA3083968C
(en)
|
2017-12-01 |
2024-04-23 |
Suzhou Ribo Life Science Co., Ltd. |
Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
|
|
WO2019105435A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN111050807B
(zh)
|
2017-12-01 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN110945130B
(zh)
|
2017-12-01 |
2024-04-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
JP7365052B2
(ja)
|
2017-12-01 |
2023-10-19 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
WO2019105437A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
EP3732185B1
(en)
|
2017-12-29 |
2025-02-26 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
EP3862024A4
(en)
|
2018-09-30 |
2022-08-17 |
Suzhou Ribo Life Science Co., Ltd. |
SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
|
|
CA3118305A1
(en)
|
2018-11-02 |
2020-05-07 |
Arbutus Biopharma Corporation |
Bivalent targeted conjugates
|
|
US12496347B2
(en)
|
2018-12-28 |
2025-12-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
CN112423795A
(zh)
|
2018-12-28 |
2021-02-26 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN113330117B
(zh)
|
2019-01-18 |
2024-05-28 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN111979237A
(zh)
|
2019-05-22 |
2020-11-24 |
苏州瑞博生物技术股份有限公司 |
核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
CN111973617A
(zh)
|
2019-05-23 |
2020-11-24 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
CN111973618B
(zh)
|
2019-05-23 |
2024-02-02 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与siRNA缀合物及制备方法和用途
|
|
CN111973619B
(zh)
|
2019-05-23 |
2024-01-30 |
苏州瑞博生物技术股份有限公司 |
核酸、含有该核酸的药物组合物与siRNA缀合物及制备方法和用途
|
|
US20220315929A1
(en)
|
2019-05-24 |
2022-10-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate, preparation method therefor and use thereof
|
|
CA3140233A1
(en)
|
2019-05-24 |
2020-12-03 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate, preparation method and use
|
|
EP3978609A4
(en)
|
2019-05-24 |
2024-02-07 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|